Cancer
Cancer Ongoing 2021 North Shore NSW

KEYNOTE-992

Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).

Trial overview

Disease
Genitourinary cancer
Topic
KEYNOTE-992
Description
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC).
Eligibility criteria
  • Muscle Invasive bladder cancer
  • Not planned for surgery 
Study details

The treatment involves immunotherapy plus chemotherapy plus radiotherapy vs the standard of care, chemotherapy with radiotherapy. While on treatment there will be regular blood tests, urine tests, cystoscopies, and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.

Location

North Shore NSW